Olodaterol

證據等級: L5

預測適應症: 2 個

Olodaterol: From COPD Maintenance to Bronchitis

One-Sentence Summary

Olodaterol (Striverdi® Respimat®) is a once-daily long-acting β2-adrenergic agonist (LABA) established as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may be effective for Bronchitis, with 3 clinical trials and 2 publications currently supporting this direction. The mechanistic rationale is strong for the chronic obstructive bronchitis phenotype, though the overall evidence grade remains observational.

Quick Overview

Item	Content
Original Indication	COPD maintenance bronchodilator therapy
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.84%
Evidence Level	L3
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, olodaterol is a selective long-acting β2-adrenergic agonist (LABA). Its established mechanism involves β2 receptor activation → Gs-protein coupling → adenylyl cyclase stimulation → intracellular cAMP elevation → PKA activation → bronchial smooth muscle relaxation. Once-daily inhalation sustains 24-hour continuous bronchodilation. Olodaterol also exerts an auxiliary anti-inflammatory effect by suppressing mast cell mediator release.

The link between COPD and bronchitis is clinically well-recognised: chronic bronchitis is itself a defining phenotype of COPD (productive cough ≥3 months/year for 2 consecutive years with airflow obstruction). In this COPD–chronic bronchitis (COPD-CB) subtype, olodaterol’s mechanism directly targets the hallmark features of excessive airway smooth muscle tone and progressive airflow limitation, making the mechanistic case compelling. By contrast, for acute infectious bronchitis — where mucosal infection and impaired mucociliary clearance dominate — the rationale is weaker.

The high TxGNN score (99.84%) reflects the close disease-class proximity between bronchitis and COPD within the knowledge graph. Multiple real-world studies that enrolled COPD patients specifically documented chronic bronchitis and emphysema as enrolled subtypes, demonstrating that the evidence base substantially overlaps with the target population. This cross-indication coherence supports the biological plausibility of the prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02850978	N/A (PMS)	Completed	1,335	Post-marketing surveillance of Tiotropium/Olodaterol (Spiolto) in Japanese COPD patients; study population explicitly includes the chronic bronchitis and emphysema subtypes; assessed long-term safety and real-world effectiveness
NCT05127304	N/A (RWE)	Completed	11,316	Large real-world comparison of TIO/OLO versus FF/UMEC/VI (triple therapy) for disease burden, healthcare costs, and clinical outcomes in COPD; population overlap with chronic bronchitis diagnosis codes
NCT03333018	N/A (DUS)	Completed	22,155	Drug utilisation study of aclidinium bromide in European COPD patients including bronchitis subpopulations; primary drug is not olodaterol — indirect evidence for patient population characterisation only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27354040	2016	Narrative Review	American Journal of Health-System Pharmacy	Comprehensive review of olodaterol pharmacology, pharmacokinetics, efficacy, and safety as a once-daily LABA; confirms established role in obstructive airway disease including chronic bronchitis subtype of COPD
25515181	2015	Clinical Practice Guideline	Basic & Clinical Pharmacology & Toxicology	Finnish national COPD guideline covering diagnosis, risk stratification, and stepwise pharmacotherapy; addresses chronic bronchitis phenotype management and the role of long-acting bronchodilators

Philippines Market Information

Olodaterol currently has no registered products in the Philippines. No authorization number, product name, or indication data is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence supporting olodaterol specifically for bronchitis is limited to observational and post-marketing studies (L3), with no direct randomised controlled trials targeting bronchitis as a primary endpoint; combined with the absence of any Philippines registration and a complete gap in local safety and MOA documentation, the data is insufficient to support a go decision at this stage.

To proceed, the following is needed:

Safety data (Blocking): Retrieve the international package insert (FDA/EMA label for Striverdi® or Spiolto® Respimat®) to extract warnings, contraindications, and key drug interactions — this is a prerequisite for any safety evaluation
MOA documentation (High priority): Query DrugBank API (DB09080) for complete mechanism of action and pharmacodynamic data to support the mechanistic rationale section
Population clarification: Define the precise target: acute infectious bronchitis (olodaterol likely not beneficial) versus chronic obstructive bronchitis/COPD-CB phenotype (strong mechanistic and indirect clinical rationale)
Regulatory pathway assessment: Evaluate Philippines FDA requirements for registering an inhaled bronchodilator not currently marketed locally; determine whether a new indication submission or a market entry application is required first
Direct clinical evidence: If pursuing the COPD-CB phenotype indication, identify existing Phase 3 subgroup analyses reporting outcomes specifically in the chronic bronchitis population from the TonaDO or OTEMTO trial programs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.